Synlogic (SYBX) Enters Cancer Collaboration With Roche
Zacks Investment Research | May 23, 2019 04:15AM ET
Synlogic, Inc. (NASDAQ:SYBX) announced that it has entered a new collaboration with large pharma company, Roche (OTC:RHHBY) . Synlogic will develop its Synthetic Biotic medicine, SYNB1891, in combination with Roche’s PD-L1 inhibitor, Tecentriq (atezolizumab), as a treatment for advanced solid tumors.
SYNB1891 is a pre-clinical stage candidate. Synlogic is expected to file an investigational new drug (“IND”) application with the FDA in the second half of 2019to initiate a phase I study to evaluate SYNB1891 as monotherapy and in combination with Tecentriq.
The study will evaluate the maximum tolerated dose of SYNB1891 in patients as monotherapy and the recommended dose for the phase II study. Synlogic will bear the whole cost of the early-stage study and Roche will supply Tecentriq for clinical development.
Shares of Synlogic have increased 22.3% so far this year compared with the industry ’s rise of 2.2%.
SYNB1891 is a non-pathogenic strain of the bacteria, E.coli, which is designed to stimulate immune response in cancerous cells.
The checkpoint inhibitors like Merck’s (NYSE:MRK) Keytruda and Bristol-Myers (NYSE:BMY) and Roche’s Tecentriq have greatly improved the treatment outcomes in cancer patients. However, there are patients who are not responsive to these therapies. Synlogic expects the combination of natural therapies and adaptive therapies like the checkpoint inhibitors to generate better antitumor immune response.
Apart from SYNB1891, Synlogic has a few other candidates in its pipeline. The two lead candidates, SYNB1020 and SYNB1618, are being developed in phase I studies for hyperammonemia (a liver disease) and phenylketonuria, respectively. Synlogic also has a collaboration with AbbVie (NYSE:ABBV) under which a candidate targeting inflammatory bowel disease is being developed.
Zacks Rank
Synlogic currently carries a Zacks Rank #3 (Hold). You can see .
Wall Street’s Next Amazon (NASDAQ:AMZN)
Zacks EVP Kevin Matras believes this familiar stock has only just begun its climb to become one of the greatest investments of all time. It’s a once-in-a-generation opportunity to invest in pure genius.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.